Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Durst, 1983, A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions, Proc Natl Acad Sci USA, 80, 3812, 10.1073/pnas.80.12.3812 2007, Human papillomaviruses, IARC Monogr Eval Carcinog Risks Hum, 90, 1 Schiffman, 2016, Carcinogenic human papillomavirus infection, Nat Rev Dis Primers, 2, 10.1038/nrdp.2016.86 Ghim, 1992, HPV-1 L1 protein expressed in COS cells displays conformational epitopes found on intact virions, Virology, 190, 548, 10.1016/0042-6822(92)91251-O Kirnbauer, 1992, Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic, Proc Natl Acad Sci USA, 89, 12 180, 10.1073/pnas.89.24.12180 Rose, 1993, Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles, J Virol, 67, 1936, 10.1128/jvi.67.4.1936-1944.1993 Lowy, 2015, Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging, Lancet Oncol, 16, e226, 10.1016/S1470-2045(15)70075-6 Luostarinen, 2018, Vaccination protects against invasive HPV-associated cancers, Int J Cancer, 142, 2186, 10.1002/ijc.31231 Draper, 2013, A randomized, observer-blinded immunogenicity trial of Cervarix and Gardasil human papillomavirus vaccines in 12–15 year old girls, PloS One, 8, 10.1371/journal.pone.0061825 Einstein, 2014, Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a phase III randomized trial, Human Vaccin Immunothers, 10, 3435, 10.4161/hv.36121 Godi, 2019, Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix or Gardasil vaccine, Vaccine, 37, 2455, 10.1016/j.vaccine.2019.03.052 Faust, 2016, Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines, Vaccine, 34, 1559, 10.1016/j.vaccine.2016.02.019 Brown, 2009, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years, J Infect Dis, 199, 926, 10.1086/597307 Wheeler, 2012, Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol, 13, 100, 10.1016/S1470-2045(11)70287-X Artemchuk, 2019, Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort, J Infect Dis, 219, 582, 10.1093/infdis/jiy545 Tsang, 2020, Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial, J Natl Cancer Inst, 112, 1030, 10.1093/jnci/djaa010 Lehtinen, 2012, Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol, 13, 89, 10.1016/S1470-2045(11)70286-8 2007, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, N Engl J Med, 356, 1915, 10.1056/NEJMoa061741 Lehtinen, 2006, Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries, Vaccine, 24, S3/233 Lehtinen, 2017, Cancer registry follow-up for 17 million person-years of a nationwide maternity cohort, Cancer Med, 6, 3060, 10.1002/cam4.1222 Syrjänen, 2009, Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy, J Gen Virol, 90, 1515, 10.1099/vir.0.007823-0 Gaiser, 2015, Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-papillomaviruses in solid organ transplant recipients, J Dermatol Sci, 77, 37, 10.1016/j.jdermsci.2014.11.002 Mariz, 2020, Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines, NPJ Vaccines, 5, 14, 10.1038/s41541-020-0165-x Lehtinen, 2006, Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy, Int J STD AIDS, 17, 237, 10.1258/095646206776253453 Lehtinen, 2006, Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing, Int J STD AIDS, 17, 517, 10.1258/095646206778145550 Muñoz, 2010, Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women, J Natl Cancer Inst, 102, 325, 10.1093/jnci/djp534 Woodhall, 2011, Impact of HPV vaccination on young women's quality of life—a five year follow-up study, Eur J Contracept Reprod Health Care, 16, 3, 10.3109/13625187.2010.536921 Eriksson, 2013, Impact of HPV16/18 vaccination on quality of life: a pilot study, Eur J Contracept Reprod Health Care, 18, 364, 10.3109/13625187.2013.801953 Sehr, 2013, High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses, PloS One, 8, 10.1371/journal.pone.0075677 2014 Villa, 2006, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, Br J Cancer, 95, 1459, 10.1038/sj.bjc.6603469 Lehtinen, 2018, Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: results of a community randomized trial (III), Int J Cancer, 143, 2299, 10.1002/ijc.31618 Schiller, 2009, Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials, J Infect Dis, 200, 166, 10.1086/599988 Pinto, 2003, Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles, J Infect Dis, 188, 327, 10.1086/376505 Pinto, 2006, Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles, Virology, 353, 451, 10.1016/j.virol.2006.06.021 Toh, 2018, Cellular immune responses 6 years following 1, 2, or 3 doses of quadrivalent HPV vaccine in Fijian girls and subsequent responses to a dose of bivalent HPV vaccine, Open Forum Infect Dis, 5, 10.1093/ofid/ofy147 Didierlaurent, 2009, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity, J Immunol, 183, 6186, 10.4049/jimmunol.0901474 Brown, 2014, Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18, Vaccine, 32, 5880, 10.1016/j.vaccine.2014.08.004 Sankaranarayanan, 2016, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study, Lancet Oncol, 17, 67, 10.1016/S1470-2045(15)00414-3 Lehtinen, 2006, Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s, Int J Cancer, 119, 2612, 10.1002/ijc.22131 Merikukka, 2011, Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33, IntJ Cancer, 128, 1114, 10.1002/ijc.25675 Lehtinen, 2018, Impact of gender-neutral or girls-only vaccination against human papillomavirus—results of a community-randomized clinical trial (I), Int J Cancer, 142, 949, 10.1002/ijc.31119 Perez, 2008, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women, Int J Cancer, 122, 1311, 10.1002/ijc.23260 Pedersen, 2007, Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant, J Adolesce Health, 40, 564, 10.1016/j.jadohealth.2007.02.015